Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
Anti-Osteopenic Effect of Nasal Salmon Calcitonin in Type 1 Osteoporotic Rats : Comparison with Subcutaneous Dosing
Masaki ICHIKAWAHiromichi NAKAMUTATakashi HOSHINOYasunao OGAWAMasao KOIDA
Author information
JOURNALS FREE ACCESS

1994 Volume 17 Issue 7 Pages 911-913

Details
Abstract

The anti-osteopenic effect of nasal salmon calcitonin (SCT) was investigated in a type 1 osteoporotic model, Wistar rats which were ovariectomized (OVX) at age of 12 weeks, and compared with that of subcutaneous SCT. It was proved that nasal (5, 10, 20 and 40 U/rat) and subcutaneous (5, 10 and 20 U/kg) administration of SCT on alternate days for 3 weeks, starting a week after OVX, prevented the osteopenic changes of tibia and lumbar vertebra; this was proved by physicochemical parameters and histomorphometrically. A clear dose-dependent effect was seen in the trabecular bone volume of a selected regions of the 5th lumbar vertebra, and the ED50s of nasal and subcutaneous SCT calculated were 7.4U/rat and 3.5U/kg, respectively. The results indicate that nasal SCT is absorbed effciently in rats with increased bone turnover to prevent rapidly developing osteopenia and that the administration route is a suitable standard method for chronically giving biodegradable anti-osteoporotic peptides to rats.

Information related to the author
© The Pharmaceutical Society of Japan
Previous article Next article
feedback
Top